Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) is -4.71% lower on its value in year-to-date trading and has touched a low of $12.17 and a high of $28.67 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BCYC stock was last observed hovering at around $13.59 in the last trading session, with the day’s loss setting it -0.25%.
Currently trading at $13.34, the stock is -7.91% and -26.75% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.2 million and changing -1.84% at the moment leaves the stock -39.11% off its SMA200. BCYC registered -26.78% loss for a year compared to 6-month loss of -40.89%. The firm has a 50-day simple moving average (SMA 50) of $18.2105 and a 200-day simple moving average (SMA200) of $21.90785.
The stock witnessed a -11.77% gain in the last 1 month and extending the period to 3 months gives it a -51.51%, and is 0.23% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.34% over the week and 6.45% over the month.
Bicycle Therapeutics Plc ADR (BCYC) has around 284 employees, a market worth around $920.73M and $36.97M in sales. Profit margin for the company is -452.39%. Distance from 52-week low is 9.61% and -53.47% from its 52-week high. The company has generated returns on investments over the last 12 months (-19.99%).
with sales reaching $5.47M over the same period.The EPS is expected to grow by 40.58% this year, but quarterly earnings will post 37.59% year-over-year. Quarterly sales are estimated to grow 2.53% in year-over-year returns.
Bicycle Therapeutics Plc ADR (BCYC) Top Institutional Holders
153.0 institutions hold shares in Bicycle Therapeutics Plc ADR (BCYC), with institutional investors hold 99.02% of the company’s shares. The shares outstanding are 69.02M, and float is at 65.57M with Short Float at 6.01%. Institutions hold 97.28% of the Float.
The top institutional shareholder in the company is BAKER BROS. ADVISORS LP with over 9.4 million shares valued at $190.26 million. The investor’s holdings represent 22.0863% of the BCYC Shares outstanding. As of 2024-06-30, the second largest holder is DEEP TRACK CAPITAL, LP with 3.49 million shares valued at $70.65 million to account for 8.2014 of the shares outstanding. The other top investors are RA CAPITAL MANAGEMENT, L.P. which holds 2.25 million shares representing 5.2937% and valued at over $45.6 million, while FCPM III SERVICES B.V. holds 4.988 of the shares totaling 2.12 million with a market value of $42.97 million.
Bicycle Therapeutics Plc ADR (BCYC) Insider Activity
The most recent transaction is an insider sale by Thompson Travis Alvin, the company’s CHIEF ACCOUNTING OFFICER. SEC filings show that Thompson Travis Alvin sold 2,686 shares of the company’s common stock on Jan 06 ’25 at a price of $15.00 per share for a total of $40290.0. Following the sale, the insider now owns 32146.0 shares.
Bicycle Therapeutics Plc ADR disclosed in a document filed with the SEC on Jan 02 ’25 that Thompson Travis Alvin (CHIEF ACCOUNTING OFFICER) sold a total of 1,750 shares of the company’s common stock. The trade occurred on Jan 02 ’25 and was made at $14.09 per share for $24658.0. Following the transaction, the insider now directly holds 34991.0 shares of the BCYC stock.
Still, SEC filings show that on Jan 03 ’25, Thompson Travis Alvin (CHIEF ACCOUNTING OFFICER) disposed off 159 shares at an average price of $14.75 for $2345.0. The insider now directly holds 34,832 shares of Bicycle Therapeutics Plc ADR (BCYC).
